The increase for Glumetza was 8%, bringing the wholesale acquisition cost (WAC) to $10.75 per pill for 1000 mg and $4.97 per pill for the 500 mg. The increase for Zegerid was 10% bringing the WAC to $11.62 per pill for both the 20 mg and 40 mg dosage strength. Roth Capital believes that the increases could cause the company's results to reach the upper end of expectations, and possibly exceed guidance.
Santarus CEO Discuses Q1 2013 Results - Earnings Call Transcript, Seeking alpha may 6th 2013: From 1st quarter - Q/A answer to question about price increases:
"We typically would take price increase on a product; usually we look at it anywhere from once to twice a year and it just depends on the market opportunity.
Just want to add, in the first quarter we had taken an 8% price increase on GLUMETZA, so that would be reflected in the financial results and then on our smaller products we had also taken some modest price increases towards the end of the quarter."
The price increases started in June 2013. therefore it will impact the 3rd and 4th Quarters. The last two Quarters Glumetza and Zegerid contributed approximately $66M. If we increase that same amount we get Glumetza $45.7M plus Zegerid $25M= $70.7M. Cycloset and Fenoglide I don't expect much from $6.3M, other revenue will probably remain the same $0.9M. I believe Uceris will produce $20M - $21M = $97.9M - 98.9M for the year.
LOL if u think hedge funds wud really waste their time on a yahoo message board trying to scare of retail investors who have 50k or less invested in a stock... thats not to say hedge funds r not criminal, but they wudnt waste their time and energy on something as meaningless as this board... they'd do it on a bigger scale...